Aethlon Medical reports encouraging results from hepatitis study

[Guest guest]

http://www.tradingmarkets.com/.site/news/Stock%20News/1891030/

Aethlon Medical reports encouraging results from hepatitis study

Sep 18, 2008 (Datamonitor via COMTEX)

Aethlon Medical has announced positive preliminary data of hepatitis C virus

infected patients treated with the Aethlon Hemopurifier, a medical device

designed to assist the immune response in combating infectious disease.

The hepatitis C virus (HCV) treated patients were among end-stage renal disease

patients enrolled in human safety studies being conducted at the Fortis

Hospital, in Delhi, India.

In the studies, robust viral load reductions were observed in tested patients

completing a three-treatment Hemopurifier protocol. The resulting data

documented that two of three HCV patients tested responded with measurable viral

load reductions during the course of three four-hour Hemopurifier treatments.

The three treatments were administered during scheduled dialysis therapy every

other day over the span of five days.

The third patient showed both increases and decreases in viral load during the

course of treatment, but demonstrated an overall reduction in follow-on viral

load tests. Given the small sample size, viral load data was averaged for all

three patients. Average initial HCV viral load was 3.13 x 108 viral units per ml

of blood. After completion of three Hemopurifier treatments, viral load was

reduced an average 57% (final 4.1x107IU/ml).

The stepwise drop in HCV viral load averaged 36% per treatment. Follow-on

testing indicated that HCV viral load was 60% lower than initial viral load

values when measured three days after final Hemopurifier treatment, and at seven

days post treatment, viral load declined to 82% below starting viral load

values. Additionally, none of the patients were being treated with antiviral

drug therapy.

Viral load measurements were performed with real-time quantitative polymerase

chain reaction (RT-PCR). Control samples were measured in duplicate while

treatment samples were generally measured in triplicate. In conclusion, the

Hemopurifier treatment of HCV infected patients undergoing dialysis resulted in

a net viral load reduction of 60 to 80% with the effects of treatment

progressing at least seven days beyond Hemopurifier treatment.

http://www.datamonitor.com

[Guest guest]

http://www.tradingmarkets.com/.site/news/Stock%20News/1891030/

Aethlon Medical reports encouraging results from hepatitis study

Sep 18, 2008 (Datamonitor via COMTEX)

Aethlon Medical has announced positive preliminary data of hepatitis C virus

infected patients treated with the Aethlon Hemopurifier, a medical device

designed to assist the immune response in combating infectious disease.

The hepatitis C virus (HCV) treated patients were among end-stage renal disease

patients enrolled in human safety studies being conducted at the Fortis

Hospital, in Delhi, India.

In the studies, robust viral load reductions were observed in tested patients

completing a three-treatment Hemopurifier protocol. The resulting data

documented that two of three HCV patients tested responded with measurable viral

load reductions during the course of three four-hour Hemopurifier treatments.

The three treatments were administered during scheduled dialysis therapy every

other day over the span of five days.

The third patient showed both increases and decreases in viral load during the

course of treatment, but demonstrated an overall reduction in follow-on viral

load tests. Given the small sample size, viral load data was averaged for all

three patients. Average initial HCV viral load was 3.13 x 108 viral units per ml

of blood. After completion of three Hemopurifier treatments, viral load was

reduced an average 57% (final 4.1x107IU/ml).

The stepwise drop in HCV viral load averaged 36% per treatment. Follow-on

testing indicated that HCV viral load was 60% lower than initial viral load

values when measured three days after final Hemopurifier treatment, and at seven

days post treatment, viral load declined to 82% below starting viral load

values. Additionally, none of the patients were being treated with antiviral

drug therapy.

Viral load measurements were performed with real-time quantitative polymerase

chain reaction (RT-PCR). Control samples were measured in duplicate while

treatment samples were generally measured in triplicate. In conclusion, the

Hemopurifier treatment of HCV infected patients undergoing dialysis resulted in

a net viral load reduction of 60 to 80% with the effects of treatment

progressing at least seven days beyond Hemopurifier treatment.

http://www.datamonitor.com

[Guest guest]

http://www.tradingmarkets.com/.site/news/Stock%20News/1891030/

Aethlon Medical reports encouraging results from hepatitis study

Sep 18, 2008 (Datamonitor via COMTEX)

Aethlon Medical has announced positive preliminary data of hepatitis C virus

infected patients treated with the Aethlon Hemopurifier, a medical device

designed to assist the immune response in combating infectious disease.

The hepatitis C virus (HCV) treated patients were among end-stage renal disease

patients enrolled in human safety studies being conducted at the Fortis

Hospital, in Delhi, India.

In the studies, robust viral load reductions were observed in tested patients

completing a three-treatment Hemopurifier protocol. The resulting data

documented that two of three HCV patients tested responded with measurable viral

load reductions during the course of three four-hour Hemopurifier treatments.

The three treatments were administered during scheduled dialysis therapy every

other day over the span of five days.

The third patient showed both increases and decreases in viral load during the

course of treatment, but demonstrated an overall reduction in follow-on viral

load tests. Given the small sample size, viral load data was averaged for all

three patients. Average initial HCV viral load was 3.13 x 108 viral units per ml

of blood. After completion of three Hemopurifier treatments, viral load was

reduced an average 57% (final 4.1x107IU/ml).

The stepwise drop in HCV viral load averaged 36% per treatment. Follow-on

testing indicated that HCV viral load was 60% lower than initial viral load

values when measured three days after final Hemopurifier treatment, and at seven

days post treatment, viral load declined to 82% below starting viral load

values. Additionally, none of the patients were being treated with antiviral

drug therapy.

Viral load measurements were performed with real-time quantitative polymerase

chain reaction (RT-PCR). Control samples were measured in duplicate while

treatment samples were generally measured in triplicate. In conclusion, the

Hemopurifier treatment of HCV infected patients undergoing dialysis resulted in

a net viral load reduction of 60 to 80% with the effects of treatment

progressing at least seven days beyond Hemopurifier treatment.

http://www.datamonitor.com

[Guest guest]

http://www.tradingmarkets.com/.site/news/Stock%20News/1891030/

Aethlon Medical reports encouraging results from hepatitis study

Sep 18, 2008 (Datamonitor via COMTEX)

Aethlon Medical has announced positive preliminary data of hepatitis C virus

infected patients treated with the Aethlon Hemopurifier, a medical device

designed to assist the immune response in combating infectious disease.

The hepatitis C virus (HCV) treated patients were among end-stage renal disease

patients enrolled in human safety studies being conducted at the Fortis

Hospital, in Delhi, India.

In the studies, robust viral load reductions were observed in tested patients

completing a three-treatment Hemopurifier protocol. The resulting data

documented that two of three HCV patients tested responded with measurable viral

load reductions during the course of three four-hour Hemopurifier treatments.

The three treatments were administered during scheduled dialysis therapy every

other day over the span of five days.

The third patient showed both increases and decreases in viral load during the

course of treatment, but demonstrated an overall reduction in follow-on viral

load tests. Given the small sample size, viral load data was averaged for all

three patients. Average initial HCV viral load was 3.13 x 108 viral units per ml

of blood. After completion of three Hemopurifier treatments, viral load was

reduced an average 57% (final 4.1x107IU/ml).

The stepwise drop in HCV viral load averaged 36% per treatment. Follow-on

testing indicated that HCV viral load was 60% lower than initial viral load

values when measured three days after final Hemopurifier treatment, and at seven

days post treatment, viral load declined to 82% below starting viral load

values. Additionally, none of the patients were being treated with antiviral

drug therapy.

Viral load measurements were performed with real-time quantitative polymerase

chain reaction (RT-PCR). Control samples were measured in duplicate while

treatment samples were generally measured in triplicate. In conclusion, the

Hemopurifier treatment of HCV infected patients undergoing dialysis resulted in

a net viral load reduction of 60 to 80% with the effects of treatment

progressing at least seven days beyond Hemopurifier treatment.

http://www.datamonitor.com